Results 121 to 130 of about 1,751 (155)
Some of the next articles are maybe not open access.
0862 Sleep Architecture with Low-Sodium Oxybate Treatment in Narcolepsy: Results from the DUET Study
SLEEPAbstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
Chad Ruoff +8 more
openaire +1 more source
SLEEP
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness (EDS) or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia.
Caroleen Drachenberg +11 more
openaire +1 more source
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness (EDS) or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia.
Caroleen Drachenberg +11 more
openaire +1 more source
SLEEP
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness or cataplexy in patients ≥7 years of age with narcolepsy, and idiopathic hypersomnia in adults.
Bruce Corser +5 more
openaire +1 more source
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness or cataplexy in patients ≥7 years of age with narcolepsy, and idiopathic hypersomnia in adults.
Bruce Corser +5 more
openaire +1 more source
SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
R Sangal +8 more
openaire +1 more source
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
R Sangal +8 more
openaire +1 more source
SLEEP
Abstract Introduction Prior studies report high incidences of psychiatric and/or neurologic comorbidities in patients with narcolepsy. Low-sodium oxybate (LXB; Xywav®) is an FDA-approved treatment for cataplexy or excessive daytime sleepiness in patients ≥7 years old with narcolepsy and for adults ...
Craig Chepke +8 more
openaire +1 more source
Abstract Introduction Prior studies report high incidences of psychiatric and/or neurologic comorbidities in patients with narcolepsy. Low-sodium oxybate (LXB; Xywav®) is an FDA-approved treatment for cataplexy or excessive daytime sleepiness in patients ≥7 years old with narcolepsy and for adults ...
Craig Chepke +8 more
openaire +1 more source
SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
Alyssa Cairns +8 more
openaire +1 more source
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
Alyssa Cairns +8 more
openaire +1 more source